

# CONCERTA® is the only ADHD therapy with OROS® technology<sup>1\*</sup>

Designed to deliver MPH at a **smooth, controlled rate** using osmotic pressure<sup>1†</sup>

- **Acts fast**—initial dose dissolves within 1 hour
- **Lasts** throughout the day, into the evening
- **Unaffected by food**—no differences in pharmacokinetic or pharmacodynamic performance when taken after a high-fat breakfast




- **Immediate-release overcoat** — provides an initial dose of MPH (22% of CONCERTA® dose) within an hour<sup>1</sup>

- **Compartment 1** } releases an ascending concentration of the remaining MPH (78% of CONCERTA® dose) via the specially engineered capsule<sup>1</sup>

- **Compartment 2** }

- **Push compartment** — provides for a smooth and controlled delivery of MPH<sup>1</sup>



**CONCERTA® 18 mg q.d.**

--- Immediate-Release MPH (MPH-IR)

— Sustained-Release MPH (MPH-SR 20 mg q.d.)

Adapted from CONCERTA® Product Monograph<sup>1</sup> and Modi B, *et al.*, 2000<sup>2</sup>

q.d. = once daily.

\* Comparative clinical significance has not been established.


† Clinical significance is unknown.

# Start with CONCERTA®

Recommended by CADDRA for first-line use in children, adolescents, and adults.<sup>3</sup>

You've decided to prescribe CONCERTA®. Make sure that's what your patient receives.

Remember:  
If it doesn't say "alza",  
it's not CONCERTA®.



## Available doses



Pill images are actual size.

**References:** 1. CONCERTA® (methylphenidate hydrochloride) Product Monograph. Janssen Inc. April 17, 2019.  
2. Modi NB, Lindemulder B, Gupta SK. Single- and multiple-dose pharmacokinetics of an oral once-a-day osmotic controlled-release OROS® (methylphenidate HCl) formulation. *J Clin Pharmacol* 2000;40:379-388.  
3. Canadian ADHD Resource Alliance. (2018). *Canadian ADHD Practice Guidelines, 4th Edition*. Toronto, ON.: Canadian ADHD Resource Alliance.



Janssen Inc. 19 Green Belt Drive | Toronto, Ontario | M3C 1L9 | [www.janssen.com/canada](http://www.janssen.com/canada)  
© 2020 Janssen Inc. | All trademarks used under license. | CP-142762E

MEMBER OF  
INNOVATIVE MEDICINES CANADA

